Interpace Biosciences, Inc. (IDXG)

OTCMKTS: IDXG · Delayed Price · USD
2.44
-0.16 (-5.97%)
Jun 2, 2023, 3:40 PM EDT - Market closed
Market Cap 4.31M
Revenue (ttm) 35.70M
Net Income (ttm) -6.20M
Shares Out 4.27M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,606
Open 2.57
Previous Close 2.60
Day's Range 2.44 - 2.57
52-Week Range 0.51 - 3.60
Beta 0.78
Analysts n/a
Price Target n/a
Earnings Date Nov 10, 2021

About IDXG

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. ... [Read more]

Sector Healthcare
IPO Date May 20, 1998
Employees 94
Stock Exchange OTCMKTS
Ticker Symbol IDXG
Full Company Profile

Financial Performance

In 2022, IDXG's revenue was $31.84 million, a decrease of -22.94% compared to the previous year's $41.31 million. Losses were -$5.87 million, -60.23% less than in 2021.

Financial Statements

News

Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results

PARSIPPANY, NJ, May 12, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2023 a...

3 weeks ago - GlobeNewsWire

Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results

PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter end...

2 months ago - GlobeNewsWire

Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern

PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2...

7 months ago - GlobeNewsWire
}

Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting

PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant mole...

8 months ago - GlobeNewsWire

Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant mol...

9 months ago - GlobeNewsWire

Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.

PARSIPPANY, NJ, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced the closing of a d...

9 months ago - GlobeNewsWire

Interpace Biosciences Announces First Quarter 2022 Financial and Business Results

PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 a...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results

PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter end...

1 year ago - GlobeNewsWire
}

Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests

PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling personalized medicine, announced today that it was termi...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director

PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal,...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering

PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering

Proceeds to be used to fund the organic growth and prospective product line acquisitions

1 year ago - GlobeNewsWire

Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans

PARSIPPANY, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new ...

1 year ago - GlobeNewsWire
}

Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related Conditions

PARSIPPANY, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant mole...

1 year ago - GlobeNewsWire

Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms

PARSIPPANY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant mole...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank

PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new ...

1 year ago - GlobeNewsWire

Interpace Pharma Solutions Announces New Capability in Spatial Biology/Precision Oncology Services

Parsippany, NJ, May 17, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that it will offer...

2 years ago - GlobeNewsWire

Interpace Biosciences Announces First Quarter 2021 Financial and Business Results

PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 ...

2 years ago - GlobeNewsWire

Interpace Biosciences Raises Full Year 2021 Revenue Guidance

Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally ...

2 years ago - GlobeNewsWire

Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis

Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability i...

2 years ago - GlobeNewsWire

Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®

Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has ag...

2 years ago - GlobeNewsWire

Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results

PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, ...

2 years ago - GlobeNewsWire

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR

Part of Company's Site Consolidation and Cost Savings Measures

2 years ago - GlobeNewsWire

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer

2 years ago - GlobeNewsWire

Interpace Biosciences Announces Acceptance for Trading on the OTCQX

PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today anno...

2 years ago - GlobeNewsWire